All Episodes
GRACEcast — 599 episodes · page 3 of 6
Managing Malignant Pleural Effusions: Tunneled Pleural Catheter
Managing Malignant Pleural Effusions: Thoracentesis
Introduction to Malignant Pleural Effusions
What is the Role of Memantine for Neuroprotection During Whole Brain Irradiation?
Palliative Radiation for Bone Metastases
Liquid Biopsies: Faster Results, Easier on Patients
BRAF: A New Target to Treat in Lung Cancer
Improved Survival in Malignant Pleural Mesothelioma with Avastin Added to Chemotherapy
Which Patients with Lung Cancer Should Receive Whole Brain Radiation Therapy?
Can We Do Better with a New Chemotherapy for Squamous Cell NSCLC?
RET in Lung Cancer: The Next Big Target?
Adding to Tarceva in a Broad NSCLC Population: Weighing Benefits with Risks
Debating EGFR Inhibitors for Squamous Cell Lung Cancer Patients
Small Cell Lung Cancer Patients Can Benefit from Immunotherapy
Immunotherapy Combinations: Best Balance of Activity and Tolerability?
Choices Among Immunotherapeutics May Be the Future of Lung Cancer Care
Immunotherapy for Non-Squamous NSCLC: Should We be Using Biomarker Selection?
Immunotherapy for Squamous Non-Small Cell Lung Cancer
Whole Brain Radiation for Brain Metastases
Serum Testing for Molecular Markers: Circulating Tumor Cells & Circulating Free DNA
Myths and Misconceptions About Bronchioloalveolar Carcinoma (BAC)
Bronchioloalveolar Carcinoma (BAC): What is It?
Questions & Answers with Drs. Pal, Luke and Wolchok about Immunotherapy for Cancer
Redefining Success and Failure in Cancer Immunotherapy Trials
The Future of Cancer Immunotherapy: Combination Treatments
The Right Time for Cancer Immunotherapy: Before or After Surgery?
Who Benefits from Immunotherapy?
Lung Cancer Immunotherapy Q&A
Benjamin Levy, MD, Hails 2015 as the Year of Lung Cancer Clinical Trials
Immunotherapy for Lung Cancer: Currently Enrolling Clinical Trials of Combination Therapies
Currently Enrolling Clinical Trials of Single Agent Immunotherapies for Patients with Lung Cancer
What We Know About Immunotherapy Treatments for Lung Cancer
Kidney Cancer Immunotherapy Q&A
Kidney Cancer Immunotherapy: Reasons for Cautious Optimism
Kidney Cancer Immunotherapy: CTLA-4 & Vaccine Clinical Trials
Kidney Cancer Immunotherapy: PD-1 Pathway Clinical Trials
Lung Squamous Cancer 201: New Promise in Treatments
Lung Squamous Cancer 201: Understanding Your Disease
Questions & Answers with Drs. Topalian and Wolchok about Immunotherapy for Melanoma
Melanoma Immunotherapy, Pt. 2: The End of the Beginning
Melanoma Immunotherapy, Pt. 1: The End of the Beginning
Immunotherapy for Melanoma, Pt. 2: Immune Checkpoints & the Drugs That Block Them
Immunotherapy for Melanoma, Pt. 1: An Overview
Questions & Answers with Drs. Davies and Atkins, and patient Rusty Cline
Why is Immunotherapy More Effective in Some Cancers Than Others? - Part 2
Why is Immunotherapy More Effective in Some Cancers Than Others? - Part 1
The Patient Perspective
Managing Immunotherapy Side Effects - Part 2
Managing Immunotherapy Side Effects - Part 1
Questions & Answers with Drs. Pardoll, Hellmann, and Luke; Moderated by Dr. West
How Immunotherapy is Administered - Part 2
How Immunotherapy is Administered - Part 1
Dr. Geoffrey Oxnard: My Top Highlight in Lung Cancer from 2014 - Liquid Biopsies
History of Immunotherapy in Cancer - Part 2
History of Immunotherapy in Cancer - Part 1
What is Immunotherapy and its Mechanisms of Action? Part 2
What is Immunotherapy and its Mechanisms of Action? Part 1
Donating to GRACE is Equivalent to a Dose of Hope
It's Possible to Live WITH Cancer
Novel EGFR Inhibitors in the Setting of Acquired Resistance
He Said, She Said - The Doctor/Patient Relationship
Questions & Answers with Bonnie Addario and Craig Uthe; Moderated by Dr. Jack West
The best thing you can do as a cancer patient...
Cost of & Access to Molecularly Targeted Therapies as Barriers to Optimal Care
The Expanding Role of Patient Self-Education & Online Communities in Molecularly Defined Subgroups
Leveraging Patient Engagement & the Role of Advocacy
Questions & Answers with Drs. Doebele and Shaw; Moderated by Craig Uthe
Current and Emerging Approaches to Acquired Resistance for ALK/ROS1
Mechanisms of ALK Resistance & Implications for Treatment
Questions & Answers with Drs. Blumenthal and Pennell; Moderated by Dr. West
Using Non/Off-Targeted Therapies in Targeted Lung Cancer Populations
Clinical Trial Design & Development of Highly Targeted Agents in the Molecular Era
Questions & Answers with Drs. Riely, Weiss and Sequist; Moderated by Dr. West
Repeat Biopsies & the Potential Value of Biologically-Informed Acquired Resistance Therapy
Life After 1st Line Targeted Therapy: What Next?
What is Acquired Resistance and How Does it Occur?
Doctors Discuss: Immunotherapy in Lung Cancer
Understanding Acquired Resistance in ALK+ Lung Cancer
Treating Brain Mets in ALK+ Lung Cancer
Are EGFR TKIs (Such as Tarceva) Effective in Lung Cancer Patients Who Are Wild Type EGFR?
Sym-004 Offers Hope for EGFR Wild Type Lung Cancer Patients
It's Time to Get Over the Lung Cancer Stigma
Molecular Testing in Early Stage Non-Small Cell Lung Cancer
Targeted Therapies for Stage III Non-Small Cell Lung Cancer
Small Cell Lung Cancer Clinical Trial: Is ECOG 2511 Right for You?
I'm Very Optimistic. For the First Time.
Do You See Advances in Treatment for Small Cell Lung Cancer in the Near Future?
Will HER2 Inhibitor Drugs Help Lung Cancer Patients?
Treating Leptomeningeal Carcinomatosis in Lung Cancer
What is the Northwestern Medical Developmental Therapeutics Institute?
How Do You Help Your EGFR Patients Make Treatment Decisions When Their Cancers Grow?
Immunotherapy Treatments for Kidney Cancer
Evaluating Biomarkers in Kidney Cancer
Will Combining Immunotherapies Better Fight Kidney Cancer?
Cabozantinib for Late Stage Kidney Cancer
Immunotherapy: What Has a Year’s Experience Taught Us Since ASCO 2013?
The Best Thing You Can Do As a Kidney Cancer Patient
RADIANT and SELECT: Is Adjuvant Erlotinib Effective in Early-Stage Lung Cancer?
Are There PD1 Biomarkers in Kidney Cancer?